BioMarin Announces Third Quarter 2014 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
BioMarin (BMRN) PT Lifted to $87 at Jefferies Posts Q3
October 24, 2014 8:24 AM EDTJefferies analyst Eun Yang reiterated a Buy rating and boosted his price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $87.00 (from $84.00) following better-than-expected product sales.
Yang commented, "Better-than-expected 3Q products sales led to ~1-3% upside revision to FY14 revenue guidance (+28-29% y/y).... More
